Peptide lexicon
Tirzepatid
Dual agonist at the GIP and GLP-1 receptors with a fatty-acid side chain; approved as a medicinal substance.
| Substance class | Peptide |
|---|---|
| CAS number | 2023788-19-2 |
| Molecular formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molar mass | 4,813 g/mol |
| Synonyms | LY3298176, GIP/GLP-1-Dual-Agonist |
| PubChem | CID 166567236 |
Structure
Tirzepatide is a linear 39-amino-acid peptide that resembles native GIP at the GIP receptor and also activates the GLP-1 receptor. A C20 diacid side chain extends its half-life through albumin binding.
State of research
Research focuses on co-activation of both incretin receptors, insulin secretion, insulin sensitivity and energy metabolism. Extensive phase III data have been published.
Status
Tirzepatide is an approved medicinal substance. The material offered here is a research reagent, not a medicinal product.
Literature
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysisBMJ, 2024 · PMID 38286487 · DOI 10.1136/bmj-2023-076410
- Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trialsDiabetologia, 2024 · PMID 38613667 · DOI 10.1007/s00125-024-06144-1
- Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysisRev Endocr Metab Disord, 2026 · PMID 41032183 · DOI 10.1007/s11154-025-09991-4
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)J Hepatol, 2024 · PMID 38851997 · DOI 10.1016/j.jhep.2024.04.031
- Tirzepatide2006 · PMID 35759552
